SERVIER CANADA WINS THE 2026 PRIX GALIEN INNOVATIVE PRODUCT AWARD

PR Newswire
Today at 1:01pm UTC

SERVIER CANADA WINS THE 2026 PRIX GALIEN INNOVATIVE PRODUCT AWARD

Canada NewsWire

OTTAWA, ON, Nov. 18, 2026 /CNW/ -- Prix Galien Canada is pleased to announce Servier Canada as the recipient of the prestigious 2026 Innovative Product Award for the development and delivery of vorasidenib (Voranigo), a once-daily oral treatment for Grade 2 IDH-mutant glioma, a rare and life-threatening form of brain cancer that often affects younger adults.

The HRF proudly congratulates Servier Canada, the recipient of the 2026 Prix Galien Canada Innovative Product award!

The Health Research Foundation (HRF) is the Canadian home of the prestigious Prix Galien Innovative Product Award, which recognizes the drug that has made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, therapeutic benefit, and innovation.

Voranigo is the first major advance for this rare form of brain cancer in nearly 25 years. It offers patients a new treatment option following surgery, when care has traditionally involved monitoring or more aggressive treatments such as radiation and chemotherapy.

In a pivotal Phase III clinical trial, Voranigo more than doubled the time patients lived without their cancer progressing and significantly delayed the need for more aggressive treatment. Canadian researchers and patients played an important role in the development of the drug, with five Canadian sites participating in the clinical trial.

"Voranigo represents the kind of breakthrough innovation this award was created to recognize," said Dr. Ernesto Schiffrin, Chair of the Prix Galien Canada Jury. "It addresses a significant unmet need and offers a new approach to treatment that can meaningfully change the course of care for patients."

"We are honoured to receive this recognition for Voranigo and, most importantly, to bring a new treatment option to patients at a critical point in their care," said Lucie Rousseau, General Manager, Servier Canada. "For patients and their families, having more time before the disease progresses — and before more aggressive treatment may be needed — can make a real difference in their daily lives."

About Health Research Foundation

The Health Research Foundation (HRF) is a Canadian non-profit organization dedicated to fostering healthcare innovation and improved patient outcomes through applied health-systems research. The HRF invests in research that reimagines how care is delivered, accessed, and experienced — focusing on bold, evidence-based solutions that drive system-wide transformation. Through strategic collaboration with leading academics, industry innovators, and partners, the HRF provides the resources and networks needed to accelerate meaningful, lasting change.

About Innovative Medicines Canada

Innovative Medicines Canada (IMC) is the voice of Canada's innovative pharmaceutical industry, representing over 40 member companies. It advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. IMC's members contribute $25 billion to the economy, support nearly 150,000 high-value jobs, and invest $3.5 billion in research and development. Guided by the Code of Ethical Practices, all IMC members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.

Health Research Foundation

SOURCE Health Research Foundation